Chord Therapeutics Company
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
The company was founded in 2014 and based in Geneva, Switzerland.
Connections
Founded Date:
2014-01-01
Employee Number:
1-10
Headquarters:
Geneva, Geneve, Switzerland, Europe
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Investors:
Eclosion SA, Omega Funds
Ipo Status:
private
City:
Geneva
Region:
Geneve
Country:
Switzerland